KNOWLEDGE FOR INNOVATION
HOW FAR BEYOND THE PILL? INNOVATING THE PHARMACEUTICAL
COMMERCIAL MODEL
KNOWLEDGE FOR INNOVATION
Our Mission
The Mack Institute creates and provides research-based guidance on managing the risks and rewards of emerging technological innovations that offer new value for customers and firms.
2
KNOWLEDGE FOR INNOVATION
A CENTRAL NODE IN A KNOWLEDGE NETWORK
3
As the pivotal link in a dynamic learning network, the Mack Institute drives successful management of innovation.
KNOWLEDGE FOR INNOVATION
Research Priorities
The activities of the Mack Institute are guided by the research priorities we have jointly developed with our industry partners, signaling issues for us to research as well as topics for our insight-building conferences.
4
MACK INSTITUTE RESEARCH PRIORITIES
RESEARCH FUNDING
CONFERENCES
PUBLICATIONS
PARTNERS + FACULTY
KNOWLEDGE FOR INNOVATION
Most pharma companies are thinking today about “beyond the pill” solutions
5
“All of my clients today are looking at solutions. Everyone is talking about creating solutions.”
Pharmaceutical Consultant A
“By 2020, payers will expect the [pharma] industry to go “beyond the medicine” by providing prophylactics and healthcare packages designed to help patients manage their health.”
PriceWaterhouseCoopers – Pharma 2020
“Pharma marketers are beginning to see the opportunity in providing value‐added programs as a focal point for differentiating the brand and developing trust among brand stakeholders alike.”
Medical Marketing & Media
Source: PriceWaterhouseCoopers, Medical Marketing & MediaMack Institute Interviews, 2013
KNOWLEDGE FOR INNOVATION
Key questions
6
•What is driving the need for innovation in pharma’scommercial business model?
•What kinds of solutions can pharmaceutical companies offer to payers and providers?
•What are the challenges in implementing customer solutions?
•What organizational changes are needed?
KNOWLEDGE FOR INNOVATION
Today, five environmental factors are putting pressure on pharma’s commercial model
• Loss of exclusivity driving loss in differentiation
•Decreasing access to physicians
• Shifting power balance towards payers
•Changing reimbursement model with more focus on outcomes
• Increasing patient advocacy and empowerment
7
KNOWLEDGE FOR INNOVATION
Loss of exclusivity driving loss in differentiation: Several key products are losing patent protection
8
0
10
20
$30B
2013
11
2014
30
2015
22
Global Product Revenue at Risk from PatentExpiration ($B)
• Oxycontin
• Aciphex
• Zometa
• Xeloda
• Nexium
• Cymbalta
• Copaxone
• Celebrex
• Abilify
• Gleevec
• NamendaKey US
Expirations
Source: ZS Associates, IMS Health – The Global Use of Medicines
0
20
40
60
80
100%
2010
Branded64%
Generic27%
Other 9%
2015
Branded53%
Generic39%
Other 8%
Percent of globalrevenues
KNOWLEDGE FOR INNOVATION
Decreasing access to physicians: Physicians and hospitals have reduced access to reps
Note: “Accessible” prescriber defined as those who see at least 70% of the reps who visit themSource: ZS Associates – AccessMonitor 2013 Executive Summary
9
• Oncology and cardiology are among the most restrictive; dermatology, allergy, and endocrinology remain relatively open
• Key drivers:‐Consolidation of community‐based providers into health systems‐Mounting pressure to see more patients in same time‐ Sunshine Act
KNOWLEDGE FOR INNOVATION
Shifting power balance towards payers: Payers are becoming more powerful and value-conscious
Source: ZS Associates
10
1990s 2000s• Physicians had primary influence on prescribing decision
• Physicians still influential, but payers able to restrict patient choice through:
‐ Prior authorization‐ Step Edits‐ Tiered access‐Co‐pays
• Payers are requiring more comparative effectiveness data from pharma, especially vs. best in class drug vs. placebo
Key Drivers• ACA requirements
• Payer consolidation
• Increase in availability of generics
• Increasing government presence
KNOWLEDGE FOR INNOVATION
Reimbursement focused on outcomes: Pharma’s role in patient adherence becomes more critical
11
Current system:Fee for Service
Potential future:
Value‐based reimburse‐
ment
Payer ProviderReimbursement based on service provided;
few quality measures
Role of Pharma: Provide therapies as requested by provider; focus on solving unmet medical needs; less explicit emphasis on cost and patient adherence
Payer ProviderRisk‐based reimbursement on quality
outcomes, capitated payment for population
Role of Pharma: Risk‐based reimbursement for only those therapies that show improved patient outcomes vs. best‐in‐class; heavy focus on patient adherence
• Common types of value‐based reimbursement programs/mechanisms:‐Accountable Care Organization (ACO)‐ Patient‐centered nursing homes‐Bundled payments‐ Pay for performance
KNOWLEDGE FOR INNOVATION
Most pharmaceutical executives believe the current pharmaceutical model needs significant repair
Name of Presenter 12
Q: Many people have raised the idea that the current commercial pharmaceutical model is broken and needs significant repair. To what extent do you agree with this assessment?
Is the Pharmaceutical Model Broken?‐ % of Respondents ‐
(n=156)
Fewer than 10% believe the model is not broken 68% believe the model is broken
3%6%
22%
44%
24%
Strongly Disagree Disagree Neutral Agree Strongly Agree
Source: Booz & Co, 2011
KNOWLEDGE FOR INNOVATION
Key questions
13
•What is driving the need for innovation in pharma’scommercial business model?
•What kinds of solutions can pharmaceutical companies offer to pharma payers and providers?
•What are the challenges in implementing customer solutions?
•What organizational changes are needed?
KNOWLEDGE FOR INNOVATION
What is a Customer Solution?
• Inside-out view: “A bundling of existing products and services to help us sell more”
• Outside-in view: “Help our customers succeed to our mutual benefit”, by:
• Enhancing their revenue and financial performance
• Decreasing their risks• Reducing their total life cycle costs
“There are products, and there are solutions: A product performs a function. A solution fulfills a human need. People want solutions.”
63% of Fortune 100 Firms claim to offer solutions. Which view prevails?
financial performance safety….
14
KNOWLEDGE FOR INNOVATION
Attributes of Superior Customer SolutionsValue Proposition
• Integrated bundles of products,
services, and information
• Customized to customer’s
requirements
• Shared risk
• Co-created with customer
• Problem solving support
• Single and accountable point of
contact
• Superior service on customer’s
terms
15
KNOWLEDGE FOR INNOVATION
Attributes of Superior Customer SolutionsValue Proposition
• Integrated bundles of products,
services, and information
• Customized to customer’s
requirements
• Shared risk
• Co-created with customer
• Problem solving support
• Single and accountable point of
contact
• Superior service on customer’s
terms
Business Model
• Deep customer insights Ability to anticipate emerging
requirements Understanding of customer
economics
• Close relationships at multiple levels
• Cross-functional teams with focus on
customer segments/key accounts
• “Have it your way” mind set
• Ability to orchestrate an ecosystem
• Risk-based contracting capabilities
• Outside-in metrics and incentives
16
KNOWLEDGE FOR INNOVATION
Value propositions of three levels of customer solutions in pharma
Customer solutions
Level 1: Bundle of products, services, and information for patient; minimal
patient support
• Therapy specific
• Leverages disease insights
• Shares a common solution program that could be technology enabled
• Provides basic education for patient and doctors
• Typically focused on increasing volume of drug
17
KNOWLEDGE FOR INNOVATION
Level 1 Solution: Merck Serono’s Easypod solution has helped increase adherence
The unmet need The Easypod Solution• Injection of human growth hormone, a business that Merck Serono is in, can leave room for errors for patients
‐ Accidental dosage changes‐ Hassle and inconvenience of administration
• Providers cannot always monitor adherence
• New Easypod system delivers Merck Serono’s Saizen HGH:
‐ User attaches SeroFine single‐use, disposable needle
‐ User positions Easypod® against the skin and administers injection by depressing the lighted injection button
‐ User detaches and disposes the used needle
• Easypod Connect software uploads injection history to a secure online database, Giving the provider a look at your injection history
• Company also set up call center for patient monitoring
• Compensation by payer (NHS) is linked to overall results
• Merck’s market share and profitability is higher
18Source: Easypod website, Mack Institute interviews
1
2
3
1
2
3
KNOWLEDGE FOR INNOVATION
Value propositions of three levels of customer solutions in pharma
Customer solutions
Level 1: Bundle of products, services, and information for patient; minimal
patient support
• Therapy specific
• Leverages disease insights
• Shares a common solution program that could be technology enabled
• Provides basic education for patient and doctors
• Typically focused on increasing volume of drug
19
Level 2: Therapy with payment contingent on performance; include patient
support
• Includes Level 1 solution, plus:
• Therapy and/or segment specific
• Leverages disease insights
• Shares a common solution program that could be technology enabled
• Pharma shares risk; pay‐for performance based reimbursement; potential for increased revenues if outcomes met
• Emphasis on patient adherence
• Potential to differentiate through vouchers and patient assistance programs
KNOWLEDGE FOR INNOVATION
Level 2 Solution: Janssen Connect aims to increase adherence; shows importance of internal champion
20
The unmet need Janssen Connect benefits How it was created
• Two of Janssen’s CNS drugs, Invega Sustenna and RisperdalConsta, made for schizophrenia and Bipolar disorder, must be administered by the physician‐ Injections need to be administered weekly or monthly depending on need
• Patient adherence can be a significant problem because of inconvenience to get to the doctor’s office and forgetfulness
• Alternate sites of care:‐ Provides injections in pharmacies, primary care offices, infusion clinics
‐ JC representatives help schedule appointments and alert physicians if there are issues
• Access and reimbursement: ‐ JC provides prior authorization support and benefit verification support
• Continuity of Therapy: ‐ Reminder to patients of future appointments
• Distribution support:‐ Ensures that all providers have drugs on hand
1
2
3
4
• Internally championed by one executive
Source: Janssen website, Mack Institute interviews
KNOWLEDGE FOR INNOVATION
Level 2 Solution: The Janssen Connect Model in action
21
KNOWLEDGE FOR INNOVATION
Value propositions of three levels of customer solutions in pharma
Customer solutions
Level 1: Bundle of products, services, and information for patient; minimal
patient support
Level 3:Integrated, co‐created solution designed to improve patient
outcomes at the best total cost
• Therapy specific
• Leverages disease insights
• Shares a common solution program that could be technology enabled
• Provides basic education for patient and doctors
• Typically focused on increasing volume of drug
• Includes Level 2, plus the following:
• Diagnosis/disease specific
• Focused on providing a suite of drugs and other care that a patient needs to improve outcomes
• Creates an ecosystem of related products from other companies
• Based on mutual trust
• Likely will require partnerships with other pharma companies
22
Level 2: Therapy with payment contingent on performance; include patient
support
• Includes Level 1 solution, plus:
• Therapy and/or segment specific
• Leverages disease insights
• Shares a common solution program that could be technology enabled
• Pharma shares risk; pay‐for performance based reimbursement; potential for increased revenues if outcomes met
• Emphasis on patient adherence
• Potential to differentiate through vouchers and patient assistance programs
KNOWLEDGE FOR INNOVATION
Key questions
23
•What is driving the need for innovation in pharma’scommercial business model?
•What kinds of solutions can pharma companies offer to payers and providers?
•What are the challenges in implementing customer solutions?
•What organizational changes are needed?
KNOWLEDGE FOR INNOVATION
Six criteria must be met to enable successful solutions
Perceived capability
Trust in pharma company
Motivated pharma company
Internal advocate within company
Strong Customer Need• Solution must improve outcomes, increase convenience,
and lower cost. There should be latent dissatisfaction with the lack of good solutions
Demand Side
Readi-ness
Supply Side
Prepa-redness
• Providers must believe that the Pharma Co. understands their need and has specialized capabilities to deliver solution. Pharma Co has access to relevant data
• Providers and Payers must be willing to trust the pharma company
• Pharma Co. must have the right internal expertise, ensure that the solution meets all regulatory requirements, and not be conflicted
• Pharma Co. must be motivated and incentivized to invest in a solution, despite its potential risk and lower gross margins
• A credible internal advocate must exist within the company to champion its cause
Right internal capabilities
24
KNOWLEDGE FOR INNOVATION
Pharma companies face many challenges when trying to successfully create customer solutions
25
•Lack of Trust / Credibility•“Inside‐out” Orientation•Lack of Patient Outcomes Data
•Weak capabilities for selling to economic buyers
•Other healthcare players more motivated to innovate
•Lack of reimbursement for incremental innovation
•High margin expectations
1
2
3
4
5
6
7
KNOWLEDGE FOR INNOVATION
Lack of trust and credibility: Our interviews showed a clear lack of trust in the industry
26
Some believe that lack of trust comes from divergent interests…
…while others point to years of pharma’sunwillingness to understand their customers’ needs
“At the end, pharma has different goals from providers and payers. Every dollar that pharma earns is a dollar that hospitals and managed care does not. So I would think of this relationship as divergent interests.”
Current Pharma investor and Former Pharma Executive
“If pharma wants to create a solution to help us, they might as well create an offering under a different name. We don’t trust them today.”
Hospital Executive
“I had a pharma rep come to my office, claiming to help provide wellness solutions. I was instantly suspicious. If you are serious about talking to us, why send a drug rep who does not understand our needs? They just doesn’t understand what we need.”
Managed Care Executive
“Every time a pharma company asks me "how can I help you?”, I’m skeptical since I think their job is to push the pill. It’s just very hard to have a fruitful conversation with this mistrust.”
Hospital Executive
Source: Mack Institute Interviews, 2013
1
KNOWLEDGE FOR INNOVATION
“Inside-out” orientation: Pharma’s business model has not required it to understand the patient
27
“We promote the best rep, but do they see the world through the customer’s eyes? No.”
Pharma executive
“If a pharma company wants to create beyond the pill solutions, it needs to have a deep patient understanding and know how they can add value. However, we haven’t needed to fully understand the patient to date.”
Pharma executive
Source: Mack Institute Interviews, 2013
2
KNOWLEDGE FOR INNOVATION
Lack of patient outcomes data: Pharma is missing key data on patient outcomes
28
Challenges created by not having access to patient outcomes data
• Lacking key data necessary for forming appropriate risk‐based contracts‐ Difficult to attribute patient outcomes to individual company’s therapies
‐ Difficult to disaggregate contribution of individual company’s drugs versus other treatment received
• Inability to monitor and standardize the use of therapies across providers to improve patient outcomes
“The use of data is a hot topic in pharma companies right now. But the truth is, pharma companies have no outcomes data, which limits what kind of solutions they can create.”
Pharma Consultant
“We tried to set up a partnership with a payer to help them standardize patient care. But in the end, they didn’t want to share the data and the partnership was shut down.”
Pharma Executive
Source: Mack Institute Interviews, 2013
3
KNOWLEDGE FOR INNOVATION
Weak capabilities for selling to economic buyers:Group selling capabilities must be built
29
Drug Rep Physician
Traditional selling model:Physician Detailing
Emerging system:Rise of
economic buyer
Drug RepHospital
Physician
Payers
Gov’t
“I would be open to pharma approaching us with a solution that can help reduce costs and improve our patient population. But to date, this has just not happened – new products introduced today aren’t attempting to create cost savings.”
Managed Care Executive
“We are in a brand new world today, facing capitated and bundled payments. We need pharma to take risk and help us reduce costs, but to date they haven’t shown us anything beyond trying to push pills..”
Provider Executive
Source: Mack Institute Interviews, 2013
4
Model requires group sell capabilities, including MSLs,
nurse educators, and reimbursement specialists
KNOWLEDGE FOR INNOVATION
Pharma needs several new capabilities in order to successfully create solutions
30
Marketing Go‐to‐market model
•Deep patient insights about issues such as:‐Why patients become less adherent
‐What complementary offerings can help improve disease management
• Insights on effect of pharma therapies on patient outcomes from outcomes data
•Risk‐based contracting capabilities
• Skill‐set to understand customer economics
• Sales teams willing to focus on key large customers such as government, payers, and large provider systems
• Sales force incentives based on solution sales, not drug volumes
4
KNOWLEDGE FOR INNOVATION
Other healthcare players more motivated to innovate:pharma faces less short term pressure
31
5
Player Pressure to innovate business model
Rationale
Providers Higher in the short term •Facing reimbursement pressure from public and private payers if patient outcomes not met
•New reimbursement models may require re‐engineering entire workflow
Payers Higher in the short term •Facing immense pressure to contain costs because of ACA
• Looking for risk‐sharing with providers to create incentives for cost reduction
Pharma Lesser in the short term •ACA had limited impact on business•Diversification into emerging markets limits US risk
KNOWLEDGE FOR INNOVATION
Lack of reimbursement for incremental innovation:New products are often not reimbursable
32
“When we tried to sell our solutions to payers, they said ‘give me the value added product, but give it to me for free’.”
Pharmaceutical Executive A
“Payers are not willing to reimburse us for a value‐added product unless it lowers costs. It’s a tough environment and showing increased efficacy is not enough.”
Pharmaceutical Executive B
“We don’t even consider incremental reimbursement for a value‐added product. The goal for this initiative is to drive higher volumes of our companion high‐margin drug.”
Pharmaceutical Executive C
Source: PriceWaterhouseCoopers, Medical Marketing & MediaMack Institute Interviews, 2013
6
KNOWLEDGE FOR INNOVATION
High margin expectations: Pharma’s high-margins make investment in low-margin businesses less attractive
33
Consequences of high‐margin orientation
• Unwillingness to disrupt own business, even in response to changing market conditions‐ Ignoring new customers and their needs
• Missing potentially lucrative opportunities
• Culture that discourages risk‐taking behavior
“Everyone talks about creating a solution, but as soon as they realize that the economics are less attractive than the current business, management cuts the project.”
Pharma Executive
“Pharma is doing everything to make sure it doesn’t destroy shareholder value. Shareholders don’t like low‐margin businesses, and no CEO wants to claim that he destroyed value.”
Pharma Executive
“My clients know that the industry is threatened and they are trying to innovate the business model. But no one wants to innovate by getting into lower‐margin businesses.”
Pharma Consultant
Source: Mack Institute Interviews, 2013
7
KNOWLEDGE FOR INNOVATION
Kodak/Fuji: Until 2001, Kodak enjoyed high margins and a strong share in film
34
Source: Thomson One, Deutsche Bank ReportsShare of Film Market
7
KNOWLEDGE FOR INNOVATION
Kodak/Fuji: As digital gained traction, Kodak’s film businesses collapsed while Fuji diversified itself
35
Fuji buys controlling stake of document processing segment
Fuji uses expertise in film to grow Flat Panel
Display Materials segment
Fuji uses film and chemicals expertise to enter cosmetics and drugs businesses
Fuji grows medical imaging
business
Kodak digital strategy relies on printing of digital photos using its printing services
Digital camera industry revenues
peak in 2008
Kodak enters highly competitive inkjet printer market
Kodak creates printers for in‐home photo
printing
Source: Thomson One, Analyst reports, The Economist
Kodak files for Chapter 11 bankruptcy
7
KNOWLEDGE FOR INNOVATION
Kodak/Fuji: Imaging, declining at 11% a year, became a small part of Fuji’s business
36
Source: Thomson One, Analyst reports, Fuji Annual Reports
7
KNOWLEDGE FOR INNOVATION
Kodak/Fuji: Several factors led to Kodak’s decline
37
• Kodak held a myopic view of its business‐Believed that it played in the film business, not the image creation and processing business
• Kodak showed an unwillingness to disrupt their business model to enter a lower‐margin, disruptive business‐Placed bet on printing of photographs despite growth of digital
• Kodak did not build the internal capabilities to succeed in digital‐Did not invest early in digital camera, which was created at Kodak in the 1970s‐Entered into a highly competitive photo printing market
“The difference between [Kodak’s] traditional business and digital was so great. The tempo is different. The kind of skills you need are different. Kay [Whitmore, President] and Colby [Chandler] would tell you that they wanted change, but they didn’t want to force pain on the organization.”
A Swasy, Changing Focus
Source: A Swasy, Changing Focus: Kodak and the Battle to Save a Great American Company, Knoeldge@Wharton, 2012
“Kodak had a choice in how it pursued innovation: If it focused on the need, it would have to find new ways to take and store photos. If it focused on the solution, it would have to find new markets for its chemical coating technologies. Kodak's competitor, Tokyo-based Fujifilm, focused on the solution, applying its film-making expertise to LCD flat-panel screens, drugs and cosmetics.”
Knowledge@Wharton, 2012
7
KNOWLEDGE FOR INNOVATION
Agenda8:30 a.m. – 9:00 a.m. BREAKFAST
9:00 a.m. – 10:15 a.m. INTRODUCTION AND REVIEW OF RESEARCH STUDY CONCLUSIONSInsights from emerging pharma marketsCommentary by Prashant Nikam, Global Marketing Lead, Mozobil and Legacy Brands,Sanofi-Aventis
10:15 a.m. – 10:45 a.m. BREAK
10:45 a.m. – 11:30 a.m. HOW CAN HEALTHCARE COMPANIES BECOME PROTAGONISTS FOR CUSTOMERS?Larry Huston, Managing Director, 4iNNO
11:30 a.m. – 12:30 p.m. PANEL: TAKING THE PROVIDERS PERSPECTIVEJim Peters, CEO, Geisinger Medical Management Corp.; S.V.P., Office of the President, Geisinger Health System; Head, Strategic Industry Partnerships & NegotiationsRoy Rosin, Chief Innovation Officer, University of Pennsylvania Hospital SystemMike Tarino, Vice President, Strategic Partnerships, Geisinger Health Plan
12:30 p.m. – 2:30 p.m. WORKING LUNCH & BREAKOUT SESSIONS
2:30 p.m. – 4:00 p.m. REPORT BACK AND NEXT STEPS
4:00 p.m. ADJOURN
KNOWLEDGE FOR INNOVATION
Working Lunch & Breakout Sessions
Small group facilitated discussions, with each group assigned to one of following topics:
(A) What are the conditions for successful level 2 or 3 customer solution? How will the barriers to success be overcome? How will technology advances, such as personalized medicines, impact the ability of pharma companies to offer solutions?
(B) How can pharma companies meet the organization requirements of level 2/3 solutions (what capabilities, incentives and structures)? What is the role of leadership?
(C) What is the profit model? When and how will pharmaceutical companies make money from customer solutions? Are there intermediate benefits (customer satisfaction, loyalty, etc.) that can be monetized?
KNOWLEDGE FOR INNOVATION
Top Related